- Report
- July 2024
- 150 Pages
Global
From €3275EUR$3,750USD£2,845GBP
- Report
- July 2024
- 100 Pages
Global
From €3275EUR$3,750USD£2,845GBP
- Report
- July 2024
- 150 Pages
Global
From €3275EUR$3,750USD£2,845GBP
- Report
- May 2025
- 104 Pages
Brazil
From €4148EUR$4,750USD£3,604GBP
- Report
- April 2023
- 112 Pages
Global
From €4148EUR$4,750USD£3,604GBP
- Report
- April 2023
- 121 Pages
Global
From €4148EUR$4,750USD£3,604GBP
- Report
- April 2023
- 100 Pages
Global
From €4148EUR$4,750USD£3,604GBP
- Report
- May 2024
- 200 Pages
Global
From €3624EUR$4,150USD£3,148GBP
- Report
- August 2023
- 145 Pages
Global
From €2751EUR$3,150USD£2,390GBP
- Report
- August 2022
- 120 Pages
Global
From €4148EUR$4,750USD£3,604GBP
- Report
- August 2022
- 110 Pages
Global
From €4148EUR$4,750USD£3,604GBP
- Report
- December 2019
- 149 Pages
Global
From €3886EUR$4,450USD£3,376GBP
- Report
- March 2024
- 150 Pages
Global
From €3886EUR$4,450USD£3,376GBP
- Report
- April 2024
- 80 Pages
China
From €655EUR$750USD£569GBP
€1310EUR$1,500USD£1,138GBP
- Report
- April 2024
- 80 Pages
France
From €655EUR$750USD£569GBP
€1310EUR$1,500USD£1,138GBP
- Report
- April 2024
- 80 Pages
Germany
From €655EUR$750USD£569GBP
€1310EUR$1,500USD£1,138GBP
- Report
- April 2024
- 80 Pages
India
From €655EUR$750USD£569GBP
€1310EUR$1,500USD£1,138GBP
- Report
- April 2024
- 80 Pages
Saudi Arabia
From €655EUR$750USD£569GBP
€1310EUR$1,500USD£1,138GBP
- Report
- April 2024
- 80 Pages
South Korea
From €655EUR$750USD£569GBP
€1310EUR$1,500USD£1,138GBP
From €655EUR$750USD£569GBP
€1310EUR$1,500USD£1,138GBP

The Drug Eluting Balloon (DEB) market is a subset of the medical device industry. DEBs are used to treat peripheral artery disease (PAD) and coronary artery disease (CAD). They are designed to deliver a drug directly to the site of the blockage, allowing for improved efficacy and reduced side effects. DEBs are typically composed of a balloon catheter with a drug-eluting coating. The drug is released when the balloon is inflated, allowing for targeted delivery of the drug to the affected area.
DEBs have been shown to be effective in treating PAD and CAD, and are increasingly being used in clinical practice. They offer a minimally invasive alternative to traditional treatments such as stenting and bypass surgery.
Some companies in the DEB market include Medtronic, Boston Scientific, Abbott, and B. Braun. Show Less Read more